Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice.

about

Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice.

Item

http://www.wikidata.org/entity/Q49592440

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Tyrosine kinase inhibitors in ...... perience in clinical practice.

@en

Tyrosine kinase inhibitors in ...... perience in clinical practice.

@nl

type

Item

label

Tyrosine kinase inhibitors in ...... perience in clinical practice.

@en

Tyrosine kinase inhibitors in ...... perience in clinical practice.

@nl

prefLabel

Tyrosine kinase inhibitors in ...... perience in clinical practice.

@en

Tyrosine kinase inhibitors in ...... perience in clinical practice.

@nl

P1476

Tyrosine kinase inhibitors in ...... perience in clinical practice.

@en

P2093

A Sebastián-Ochoa

http://www.w3.org/2001/XMLSchema#string

F Tinahones-Madueño

http://www.w3.org/2001/XMLSchema#string

I Mancha-Doblas

http://www.w3.org/2001/XMLSchema#string

J García-Alemán

http://www.w3.org/2001/XMLSchema#string

J M Trigo-Pérez

http://www.w3.org/2001/XMLSchema#string

M Molina-Vega

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of advanced thyroid cancer with targeted therapies: ten years of experience

A new appraisal of iodine refractory thyroid cancer

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer

Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review.

A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses.

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

The impact of age and gender on papillary thyroid cancer survival.

P2888

s12020-017-1499-7

P304

395-401

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12020-017-1499-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29275532

http://www.w3.org/2001/XMLSchema#string